🔬 Mechanism of Action

Lenvatinib inhibits various RTKs, including:

• Vascular Endothelial Growth Factor Receptors (VEGFR1–3)

• Fibroblast Growth Factor Receptors (FGFR1–4)

• Platelet-Derived Growth Factor Receptor Alpha (PDGFRα)

• KIT and RET

By blocking these receptors, Lenvatinib impedes tumor vascularization and proliferation, thereby slowing cancer progression.

💊 Indications

Lenvaxen 4 mg is prescribed for:

• Differentiated Thyroid Cancer (DTC): For patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory DTC.

• Renal Cell Carcinoma (RCC): In combination with Everolimus for advanced RCC following one prior anti-angiogenic therapy.

• Hepatocellular Carcinoma (HCC): As a first-line treatment for unresectable HCC.

• Endometrial Carcinoma: In combination with Pembrolizumab for advanced endometrial carcinoma that is not microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), following prior systemic therapy. 

📦 Packaging

• Formulation: Capsule

• Strength: 4 mg of Lenvatinib per capsule

• Packaging: Each child-resistant HDPE container contains 30 capsules. 

⚠️ Side Effects & Precautions

Common side effects include:

• Hypertension

• Diarrhea

• Fatigue

• Decreased appetite

• Weight loss

• Nausea

• Proteinuria

• Stomatitis

• Headache

• Vomiting

Serious adverse events may encompass:

• Cardiac dysfunction

• Arterial thromboembolic events

• Hepatotoxicity

• Renal impairment

• QT interval prolongation

• Hemorrhagic events

• Gastrointestinal perforation

• Reversible posterior leukoencephalopathy syndrome

Contraindications:

• Known hypersensitivity to Lenvatinib or any component of the formulation.

• Pregnancy and lactation due to potential harm to the fetus or infant. 

Precautions:

• Regular monitoring of blood pressure, liver function, and proteinuria is advised.

• Dose adjustments may be necessary for patients with renal or hepatic impairment.

• Use effective contraception during treatment and for at least 30 days after the last dose.

📌 Administration Guidelines

• Dosage:

  • DTC: 24 mg orally once daily.

  • RCC: 18 mg orally once daily in combination with 5 mg Everolimus.

  • HCC: Based on body weight—12 mg for patients ≥60 kg; 8 mg for patients <60 kg.

  • Endometrial Carcinoma: 20 mg orally once daily in combination with Pembrolizumab 200 mg intravenously every 3 weeks.

• Administration:

  • Take at the same time each day, with or without food.

  • If a dose is missed and cannot be taken within 12 hours, skip the missed dose and take the next dose at the regular time.